Jonathan Beer

Bristol Myers Squibb

Jonathan Beer joined BMS in 2023 and leads the diagnostic strategy and CDx development of multiple global investigational new drug Phase III clinical trials assays across technology and sample types to select patients for enrollment. Prior to BMS he was with Novartis for more than a decade and contributed to 7 Pre-Market Approval submissions to the US FDA for Companion Diagnostic Assays and was the lead for the CDx assay of alpelisib which was the 2nd liquid biopsy CDx approved by the FDA and only contemporaneous approval for multiple sample types in a submission. In addition to clinical support, Jonathan has led a research lab identifying new and emerging technologies, performed feasibility testing of selected platforms or vendors, and recommended assays will the highest impact exploratory biomarker data to drug development teams. Jonathan is a member of the BLOODPAC consortium and shares their mission to help improve patient outcomes through Liquid Biopsy.

Disclosure information not submitted.

Presentation(s):

• Standardization and automation for liquid biopsy solutions in oncology

  Tuesday, February 6, 2024
  8:30 AM – 10:00 AM EST